Three biotechs, two Chinese issuers, and one SPAC went public this past week, led by preclinical oncology biotech Nkarta (NKTX), which popped 166% in the best first-day return for a $10+ million IPO since 2015. Some major news hit the IPO pipeline this...read more
Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of $16 to $17. The company offered 1 million more shares than anticipated....read more
Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised the proposed deal size for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $215 million by offering 13 million...read more
Updated Monday, 7/6. Following the long weekend, two Chinese IPOs, two biotechs, and a SPAC are currently scheduled to list in the US in the week ahead, inlcuding China’s largest LGBTQ dating app BlueCity (BLCT). More deals could join the IPO...read more
US IPO Weekly Recap: Preclinical biotech Nkarta pops 166% in a 5 IPO week
Three biotechs, two Chinese issuers, and one SPAC went public this past week, led by preclinical oncology biotech Nkarta (NKTX), which popped 166% in the best first-day return for a $10+ million IPO since 2015. Some major news hit the IPO pipeline this...read more
Preclinical oncology biotech Nkarta prices further upsized IPO at $18, above the upwardly revised range
Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of $16 to $17. The company offered 1 million more shares than anticipated....read more
Preclinical oncology biotech Nkarta raises proposed deal size by 43% ahead of $215 million IPO
Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised the proposed deal size for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $215 million by offering 13 million...read more
US IPO Week Ahead: Third quarter kicks off with China’s largest gay dating app
Updated Monday, 7/6. Following the long weekend, two Chinese IPOs, two biotechs, and a SPAC are currently scheduled to list in the US in the week ahead, inlcuding China’s largest LGBTQ dating app BlueCity (BLCT). More deals could join the IPO...read more